multivessel

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus after ST-Segment Elevation Acute Coronary Syndrome

The incidence of left ventricular thrombosis (LVT) after anterior ST-segment elevation myocardial infarction (STEMI) ranges from 4% to 26%. This is associated with bad long-term evolution. In the past, triple-scheme therapy (vitamin K antagonist plus dual antiplatelet therapy) was recommended to prevent LVT, despite the lack of high-quality scientific evidence and an increase in the<a href="https://solaci.org/en/2022/05/05/prophylactic-rivaroxaban-therapy-for-left-ventricular-thrombus-after-st-segment-elevation-acute-coronary-syndrome/" title="Read more" >...</a>

ACC 2022

ACC 2022 | COMPLETE

Percutaneous coronary intervention improves angina related quality of life in AMI patients with multivessel disease. The COMPLETE study has shown patients receiving complete revascularization compared against culprit-only revascularization presented lower cardiovascular rate or AMI at 3-year followup. ACC featured a COMPLETE subanalysis assessing angina related quality of life.&nbsp; It included 4041 patients, mean age 62,<a href="https://solaci.org/en/2022/04/11/acc-2022-complete/" title="Read more" >...</a>

ACC 2022

ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated a change in ACC/AHA 2021 revascularization guidelines. However, its impact on quality of life is yet to be studied.&nbsp; The aim of this prespecified analysis of the COMPLETE study is to determine whether complete revascularization improves quality of<a href="https://solaci.org/en/2022/04/05/acc-2022-complete-trial-qol-complete-revascularization-in-stemi/" title="Read more" >...</a>

¿Hay diferencias entre mujeres y hombres luego de una intervención percutánea?

Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities, require less aggressive treatments, have greater long-term morbidity rates and worst functional status and/or post-procedure angina. This study used data from the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non primary Percutaneous Coronary Intervention) to assess baseline differences<a href="https://solaci.org/en/2022/04/04/are-there-differences-between-women-and-men-after-a-percutaneous-intervention/" title="Read more" >...</a>

stent

STEMI: Can We Omit Stenting?

The recommended treatment for ST elevation acute myocardial infarction (STEMI) is early PCI, typically stenting. However, stent implantation always involves the risk of intravascular complications, such as stent thrombosis or restenosis.&nbsp;&nbsp; Sometimes stable flow is restored to the target vessel after initial PCI and we can omit stenting when there is no angiographically significant residual<a href="https://solaci.org/en/2022/04/04/stemi-can-we-omit-stenting/" title="Read more" >...</a>

Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in acute coronary syndromes (ACS). However, this therapy encompasses increased bleeding, especially in elderly patients increasingly undergoing percutaneous intervention. Even though most bleeding events might not be fatal (many of them are mostly digestive) they do involve higher hospitalization<a href="https://solaci.org/en/2022/03/21/ticagrelor-monotherapy-after-3-months-is-the-current-strategy-worth-changing/" title="Read more" >...</a>

The Most Relevant of 2021 In Coronary Disease

This last year, new data in coronary disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence.&nbsp; In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most<a href="https://solaci.org/en/2022/01/06/the-most-relevant-of-2021-in-coronary-disease/" title="Read more" >...</a>

The Most Read Articles of 2021: Coronary Disease

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. Most Read Articles on Coronary Disease 01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-coronary-disease/" title="Read more" >...</a>

AHA 2021 | RAPID CABG: seguridad de ir al quirófano precozmente en un síndrome coronario agudo

AHA 2021 | RAPID CABG: Safety of Early Surgical Intervention in Acute Coronary Syndrome

Suspending ticagrelor a couple of days before surgery was non-inferior to waiting 5-6 days in terms of bleeding in patients with acute coronary syndrome (ACS) requiring myocardial revascularization surgery. Patients who waited longer had more ischemic events and longer hospitalizations. Current American guidelines recommend waiting at least 5&nbsp;days before operating on patients with ACS who<a href="https://solaci.org/en/2021/11/23/aha-2021-rapid-cabg-safety-of-early-surgical-intervention-in-acute-coronary-syndrome/" title="Read more" >...</a>

TCT 2021 | OPTIMUM: Anatomía compleja y no elegibles para cirugía ¿aceptamos el caso?

TCT 2021 | OPTIMUM: Surgically Ineligible Patients with Complex Anatomy: Do We Accept the Case?

In surgically ineligible patients with complex coronary anatomy short term risk of death with PCI is considerably lower than the estimated surgical risk. These are the outcomes of the OPTIMUM registry, presented during the TCT scientific sessions.&nbsp; The good short-term outcomes highlight the importance of trying percutaneous revascularization to treat complex patients.&nbsp; The current data<a href="https://solaci.org/en/2021/11/11/tct-2021-optimum-surgically-ineligible-patients-with-complex-anatomy-do-we-accept-the-case/" title="Read more" >...</a>

Top